T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF
- 112 Downloads
Activated leukocytes may contribute to the development and progression of heart failure (HF). We investigated the predictive value of circulating levels of stable and readily detectable markers reflecting both monocyte/macrophage and T-cell activity, on clinical outcomes in HF patients with reduced ejection fraction (HFrEF).
The association between baseline plasma levels of soluble CD163 (sCD163), macrophage migration inhibitory factor (MIF), granulysin, soluble interleukin-2 receptor (sIL-2R), and activated leukocyte cell adhesion molecule (ALCAM) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anemia, enrolled in the Reduction of Events by darbepoetin alfa in Heart Failure (RED-HF) trial. Modifying effects and interaction with darbepoetin alfa treatment were also assessed.
All leukocyte markers, except granulysin, were associated with the primary outcome and all-cause death in univariate analysis (all p < 0.01) and remained significantly associated in multivariable analysis adjusting for conventional clinical variables (e.g. age, gender, BMI, NYHA class, creatinine, LVEF, etiology) and CRP. However, after final adjustment for TnT and NT-proBNP no associations were found with outcomes. No interaction with darbepoetin alpha treatment was observed for any marker.
Leukocyte activation markers sCD163, MIF, sIL-2R, and ALCAM were associated with adverse outcome in patients with HFrEF, but add little as prognostic markers on top of established biochemical risk markers.
Clinical Trial Registration
KeywordsLeukocyte Monocyte Macrophage T cell Heart failure Prognosis
Compliance with ethical standards
Conflict of interest
Inder Anand, John J. V. Mcmurray, Dirk J. van Veldhuisen and James Young are members of the RED-HF Executive Committee—no payments in the last 12 months. John J. V. Mcmurray has received travel and accommodation costs paid by Cytokinetics/Amgen in relation to advisory board and clinical trial meetings about omecamtiv mecarbil.
- 4.Radenovic S, Loncar G, Busjahn A, Apostolovic S, Zdravkovic M, Karlicic V, Veskovic J, Tahirovic E, Butler J, Dungen HD (2018) Systemic inflammation and functional capacity in elderly heart failure patients. Clin Res Cardiol 107(4):362–367. https://doi.org/10.1007/s00392-017-1195-x CrossRefPubMedGoogle Scholar
- 8.Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH, Goldberg LR, Jessup M, Cappola TP (2012) Multiple biomarkers for risk prediction in chronic heart failure. Circulation Heart Fail 5(2):183–190. https://doi.org/10.1161/CIRCHEARTFAILURE.111.965020 CrossRefGoogle Scholar
- 11.von Haehling S, Gremmler U, Krumm M, Mibach F, Schon N, Taggeselle J, Dahm JB, Angermann CE (2017) Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: the PrEP registry. Clin Res Cardiol 106(6):436–443. https://doi.org/10.1007/s00392-016-1073-y CrossRefGoogle Scholar
- 12.Riedel O, Ohlmeier C, Enders D, Elsasser A, Vizcaya D, Michel A, Eberhard S, Schlothauer N, Berg J, Garbe E (2018) The contribution of comorbidities to mortality in hospitalized patients with heart failure. Clin Res Cardiol 107(6):487–497. https://doi.org/10.1007/s00392-018-1210-x CrossRefPubMedGoogle Scholar
- 14.Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM (2002) Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol 72(4):711–717PubMedGoogle Scholar
- 19.Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O’Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ, Committees R-H, Investigators R-H (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368(13):1210–1219. https://doi.org/10.1056/NEJMoa1214865 CrossRefPubMedGoogle Scholar
- 20.McMurray JJ, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB (2009) Design of the reduction of events with darbepoetin alfa in heart failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11(8):795–801. https://doi.org/10.1093/eurjhf/hfp098 CrossRefPubMedGoogle Scholar
- 21.McMurray JJ, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB, Investigators R-HC (2013) Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF). Eur J Heart Fail 15(3):334–341. https://doi.org/10.1093/eurjhf/hfs204 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M, Miklasz P, Jakim P, Galar B, Musial WJ, Kaminski KA (2016) Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure. Cytokine 80:7–12. https://doi.org/10.1016/j.cyto.2016.02.005 CrossRefPubMedGoogle Scholar
- 23.Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Froland SS, Aukrust P (2001) Effect of metoprolol on cytokine levels in chronic heart failure—a substudy in the metoprolol controlled-release randomised intervention trial in heart failure (MERIT-HF). Am Heart J 141(3):418–421. https://doi.org/10.1067/mhj.2001.112785 CrossRefPubMedGoogle Scholar
- 25.Suthahar N, Meijers WC, Brouwers FP, Heerspink HJL, Gansevoort RT, van der Harst P, Bakker SJL, de Boer RA (2018) Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. Int J Cardiol 250:188–194. https://doi.org/10.1016/j.ijcard.2017.10.035 CrossRefPubMedGoogle Scholar
- 28.Kristal B, Shurtz-Swirski R, Shasha SM, Manaster J, Shapiro G, Furmanov M, Hassan K, Weissman I, Sela S (1999) Interaction between erythropoietin and peripheral polymorphonuclear leukocytes in hemodialysis patients. Nephron 81(4):406–413. https://doi.org/10.1159/000045324 CrossRefPubMedGoogle Scholar
- 31.Martiney JA, Sherry B, Metz CN, Espinoza M, Ferrer AS, Calandra T, Broxmeyer HE, Bucala R (2000) Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemia. Infect Immun 68(4):2259–2267CrossRefPubMedPubMedCentralGoogle Scholar
- 32.McDevitt MA, Xie J, Ganapathy-Kanniappan S, Griffith J, Liu A, McDonald C, Thuma P, Gordeuk VR, Metz CN, Mitchell R, Keefer J, David J, Leng L, Bucala R (2006) A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J Exp Med 203(5):1185–1196. https://doi.org/10.1084/jem.20052398 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Pereira R, Costa E, Goncalves M, Miranda V, do Sameiro Faria M, Quintanilha A, Belo L, Lima M, Santos-Silva A (2010) Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodial Int Symp Home Hemodial 14(3):295–301. https://doi.org/10.1111/j.1542-4758.2010.00450.x CrossRefGoogle Scholar
- 35.Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, Braunwald E (2007) Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 115(24):3071–3078. https://doi.org/10.1161/CIRCULATIONAHA.106.666511 CrossRefPubMedGoogle Scholar
- 36.Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, Walston J, Lange LA, Cushman M, Tracy RP (2013) Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arteriosclerosis Thromb Vascular Biol 33 (1):158–164. https://doi.org/10.1161/ATVBAHA.112.300421 CrossRefGoogle Scholar